Ten things you should know about protein kinases: IUPHAR Review 14

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2675-2700

  Fabbro, Doriano ^a   Cowan Jacob, Sandra W ^b   Moebitz, Henrik ^b  

^a Piqur Therapeutics AG   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BCR ABL PROTEIN; BOSUTINIB; CABOZANTINIB; CERITINIB; CRIZOTINIB; DABRAFENIB; DASATINIB; EVEROLIMUS; FASUDIL; GEFITINIB; IBRUTINIB; IDELALISIB; IMATINIB; LAPATINIB; NILOTINIB; PAZOPANIB; PONATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TOFACITINIB; TRAMETINIB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ACYLATION; CATALYSIS; CHROMOSOME REARRANGEMENT; GENE AMPLIFICATION; GENE MUTATION; GLYCOSYLATION; HUMAN; METHYLATION; NITROSYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; UBIQUITINATION; DRUG DEVELOPMENT; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84928907224     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13096     Document Type: Review

References (298)

1. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. (2006). Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2: 95-102.
2. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D, (2013). MEK and the inhibitors: from bench to bedside. J Hematol Oncol 6: 27.
3. Akinleye A, Furqan M, Adekunle O, (2014). Ibrutinib and indolent B-cell lymphomas. Clin Lymphoma Myeloma Leuk 14: 253-260.
4. Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, et al. (2008). Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 51: 2879-2882.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
7. Ali S, Ali S, (2007). Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 401: 38-45.
8. Amsberg GK, Koschmieder S, (2013). Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther 6: 99-106.
9. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR, (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29: 1039-1045.
10. Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, et al. (2012). Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov 2: 512-523.
11. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. (2013). Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 342: 866-871.
12. Ansari J, Hussain SA, Ansari A, Glaholm J, (2013). Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. Biologics 7: 39-46.
13. Apperley JF, (2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029.
14. Azam M, Raz T, Nardi V, Opitz SL, Daley GQ, (2003). A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online 5: 204-210.
15. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ, (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15: 1109-1118.
16. Ballantyne AD, Garnock-Jones KP, (2013). Dabrafenib: first global approval. Drugs 73: 1367-1376.
17. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044.
18. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, et al. (2003). Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
19. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, et al. (2001). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-1914.
20. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, et al. (2005). Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408.
21. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
22. Bartholomeusz C, Gonzalez-Angulo AM, (2012). Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 121-130.
23. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529.
24. Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, et al. (2014). Everolimus plus exemestane as first-line therapy in HR(+), HER2(-) advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 143: 459-467.
25. Bishop AC, (2004). A hot spot for protein kinase inhibitor sensitivity. Chem Biol 11: 587-589.
26. Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horvath Z, et al. (2004). Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11: 691-701.
27. Blume-Jensen P, Hunter T, (2001). Oncogenic kinase signalling. Nature 411: 355-365.
28. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, et al. (2013). Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 23: 477-488.
29. Bornancin F, (2011). Ceramide kinase: the first decade. Cell Signal 23: 999-1008.
30. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR, (2006). Emerging roles of pseudokinases. Trends Cell Biol 16: 443-452.
31. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, et al. (2012). JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22: 796-811.
32. Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, et al. (2014). Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344: 1249783.
33. Buchdunger E, Matter A, Druker BJ, (2001). Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551: M11-M18.
34. Busschots K, Lopez-Garcia LA, Lammi C, Stroba A, Zeuzem S, Piiper A, et al. (2012). Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem Biol 19: 1152-1163.
35. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. (2013). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32-42.
36. Carlomagno F, Santoro M, (2004). Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemother 16 (Suppl. 4): 49-51.
37. Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, et al. (2010). Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS ONE 5: e9777.
38. Chan HY, Grossman AB, Bukowski RM, (2010). Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther 27: 495-511.
39. Chandarlapaty S, (2012). Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2: 311-319.
40. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. (2011). Akt inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
41. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
42. Chau NG, Haddad RI, (2013). Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 19: 524-529.
43. Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, et al. (2005). A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 338: 136-142.
44. Cheng H, Force T, (2010). Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 53: 114-120.
45. Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M, (2006). Patterns of pulmonary complications associated with sirolimus. Respiration 73: 367-374.
46. Chico LK, Van Eldik LJ, Watterson DM, (2009). Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 8: 892-909.
47. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
48. Chong CR, Janne PA, (2013). The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19: 1389-1400.
49. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, et al. (2014). International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol Rev 66: 918-947.
50. Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, et al. (2013). Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 95: 933-942.
51. Cohen MS, Hadjivassiliou H, Taunton J, (2007). A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat Chem Biol 3: 156-160.
52. Cohen P, (2001). The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 268: 5001-5010.
53. Cohen P, (2002a). The origins of protein phosphorylation. Nat Cell Biol 4: E127-E130.
54. Cohen P, (2002b). Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315.
55. Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, et al. (2011). Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem Biol 6: 234-244.
56. Converso A, Hartingh T, Garbaccio RM, Tasber E, Rickert K, Fraley ME, et al. (2009). Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 19: 1240-1244.
57. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, et al. (2003). PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 3: 459-469.
58. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, et al. (2004). Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 64: 6385-6389.
59. Corcoran RB, Settleman J, Engelman JA, (2011). Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2: 336-346.
60. Courtney KD, Corcoran RB, Engelman JA, (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
61. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. (2000). Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758-1766.
62. Cowan-Jacob SW, (2006). Structural biology of protein tyrosine kinases. Cell Mol Life Sci 63: 2608-2625.
63. Cowan-Jacob SW, Moebitz H, Fabbro D, (2009). Structural biology contributions to tyrosine kinase drug discovery. Curr Opin Cell Biol 21: 280-287.
64. Cowan-Jacob SW, Jahnke W, Knapp S, (2014). Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Med Chem 6: 541-561.
65. Dalzell MD, (2013). Ponatinib pulled off market over safety issues. Manag Care 22: 42-43.
66. Daub H, Specht K, Ullrich A, (2004). Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3: 1001-1010.
67. Davies SP, Reddy H, Caivano M, Cohen P, (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
68. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-1051.
69. Dibb NJ, Dilworth SM, Mol CD, (2004). Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4: 718-727.
70. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
71. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
72. Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bosse R, et al. (2008). The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics 1: 2-10.
73. Engelman JA, (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
74. Engelman JA, Settleman J, (2008a). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18: 73-79.
75. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
76. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. (2008b). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
77. Fabbro D, Garcia-Echeverria C, (2002a). Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Devel 5: 701-712.
78. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, et al. (2002b). Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93: 79-98.
79. Fabbro D, Fendrich G, Guez V, Meyer T, Furet P, Mestan P, et al. (2005). Targeted therapy with imatinib: an exception or a rule? Handb Exp Pharmacol 167: 361-389.
80. Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, et al. (2010). Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta 1804: 454-462.
81. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G, (2011). Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795: 1-34.
82. Fabbro D, Cowan SW, Möbitz H, Martiny-Baron G, (2012). Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795: 1-34.
83. Faivre S, Demetri G, Sargent W, Raymond E, (2007). Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745.
84. Fedorov O, Muller S, Knapp S, (2010). The (un)targeted cancer kinome. Nat Chem Biol 6: 166-169.
85. Felip E, Santarpia M, Rosell R, (2007). Emerging drugs for non-small-cell lung cancer. Expert Opin Emerg Drugs 12: 449-460.
86. Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, et al. (2008). Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134: 793-803.
87. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
88. Fleishman SJ, Schlessinger J, Ben-Tal N, (2002). A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A 99: 15937-15940.
89. Fletcher JA, Rubin BP, (2007). KIT mutations in GIST. Curr Opin Genet Dev 17: 3-7.
90. Force T, Krause DS, Van Etten RA, (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332-344.
91. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. (2014). The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4: 662-673.
92. Fruman DA, Rommel C, (2014). PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140-156.
93. Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. (2014). Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 370: 2352-2354.
94. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304.
95. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, et al. (2013). A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J 451: 313-328.
96. Garay JP, Gray JW, (2012). Omics and therapy-a basis for precision medicine. Mol Oncol 6: 128-139.
97. Gaul MD, Guo Y, Affleck K, Cockerill GS, Gilmer TM, Griffin RJ, et al. (2003). Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. Bioorg Med Chem Lett 13: 637-640.
98. Glossmann H, Presek P, Eigenbrodt E, (1981). Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src. Naunyn Schmiedebergs Arch Pharmacol 317: 100-102.
99. Goldman JM, Druker BJ, (2001). Chronic myeloid leukemia: current treatment options. Blood 98: 2039-2042.
100. Goldstein DM, Gray NS, Zarrinkar PP, (2008). High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 7: 391-397.
101. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. (2014). PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370: 1008-1018.
102. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
103. Gottesman MM, (2002). Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
104. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. (2002). Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
105. Gray-Schopfer V, Wellbrock C, Marais R, (2007). Melanoma biology and new targeted therapy. Nature 445: 851-857.
106. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
107. Guertin KR, Grimsby J, (2006). Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem 13: 1839-1843.
108. Hall MD, Handley MD, Gottesman MM, (2009). Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30: 546-556.
109. Hall-Jackson CA, Goedert M, Hedge P, Cohen P, (1999). Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18: 2047-2054.
110. Hanks SK, Hunter T, (1995). Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9: 576-596.
111. Hanks SK, Quinn AM, Hunter T, (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52.
112. Hardie DG, (2014). AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol 33C: 1-7.
113. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798.
114. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
115. Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, et al. (2013). Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501: 232-236.
116. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
117. Heinrich T, Gradler U, Bottcher H, Blaukat A, Shutes A, (2010). Allosteric IGF-1R Inhibitors. ACS Med Chem Lett 1: 199-203.
118. Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, et al. (2013). Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 23: 489-501.
119. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R, (2006). Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12: 4441s-4445s.
120. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y, (1984). Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23: 5036-5041.
121. Hill ZB, Perera BG, Andrews SS, Maly DJ, (2012). Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. ACS Chem Biol 7: 487-495.
122. Hindie V, Stroba A, Zhang H, Lopez-Garcia LA, Idrissova L, Zeuzem S, et al. (2009). Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat Chem Biol 5: 758-764.
123. Hoesel B, Schmid JA, (2013). The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 86.
124. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, et al. (2013). RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23: 594-602.
125. Hoy SM, (2014). Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs 74: 793-806.
126. Hsieh AC, Moasser MM, (2007). Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97: 453-457.
127. Hunter T, (2000). Signaling-2000 and beyond. Cell 100: 113-127.
128. Hynes NE, Lane HA, (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
129. Inagaki M, Kawamoto S, Itoh H, Saitoh M, Hagiwara M, Takahashi J, et al. (1986). Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors. Mol Pharmacol 29: 577-581.
130. Jahnke W, Grotzfeld RM, Pelle X, Strauss A, Fendrich G, Cowan-Jacob SW, et al. (2010). Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc 132: 7043-7048.
131. Janne PA, Gray N, Settleman J, (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723.
132. Jia Y, Gu XJ, Brinker A, Warmuth M, (2008). Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert Opin Drug Discov 3: 959-978.
133. Jin J, Pawson T, (2012). Modular evolution of phosphorylation-based signalling systems. Philos Trans R Soc Lond B Biol Sci 367: 2540-2555.
134. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
135. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J, (2011). Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42: 9-22.
136. Kannan N, Taylor SS, (2008). Rethinking pseudokinases. Cell 133: 204-205.
137. Kannan N, Taylor SS, Zhai Y, Venter JC, Manning G, (2007). Structural and functional diversity of the microbial kinome. PLoS Biol 5: e17.
138. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA, (2013). Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 31: 3600-3604.
139. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
140. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120ra117.
141. Kawai T, Akira S, (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
142. Kelly PA, Gruber SA, Behbod F, Kahan BD, (1997). Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 17: 1148-1156.
143. Kennelly PJ, (2002). Protein kinases and protein phosphatases in prokaryotes: a genomic perspective. FEMS Microbiol Lett 206: 1-8.
144. Kennelly PJ, (2003). Archaeal protein kinases and protein phosphatases: insights from genomics and biochemistry. Biochem J 370: 373-389.
145. King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al. (2013). Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS ONE 8: e67583.
146. Knapp S, Arruda P, Blagg J, Burley S, Drewry DH, Edwards A, et al. (2013). A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 9: 3-6.
147. Knight JD, Pawson T, Gingras AC, (2013). Profiling the kinome: current capabilities and future challenges. J Proteomics 81: 43-55.
148. Knight ZA, Shokat KM, (2005). Features of selective kinase inhibitors. Chem Biol 12: 621-637.
149. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
150. Kornev AP, Haste NM, Taylor SS, Eyck LF, (2006). Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A 103: 17783-17788.
151. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
152. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811.
153. Kunkel GT, Maceyka M, Milstien S, Spiegel S, (2013). Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 12: 688-702.
154. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN, (1993). Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73: 585-596.
155. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102: 7665-7670.
156. Lahiry P, Torkamani A, Schork NJ, Hegele RA, (2010). Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 11: 60-74.
157. Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, et al. (2011). Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem 286: 39247-39258.
158. Lemmon MA, Schlessinger J, (2010). Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
159. Levitzki A, (1990). Tyrphostins-potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 40: 913-918.
160. Li B, Liu Y, Uno T, Gray N, (2004). Creating chemical diversity to target protein kinases. Comb Chem High Throughput Screen 7: 453-472.
161. Li M, Youngren JF, Manchem VP, Kozlowski M, Zhang BB, Maddux BA, et al. (2001). Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells. Diabetes 50: 2323-2328.
162. Lin K, Lin J, Wu W-I, Ballard J, Lee BB, Gloor SL, et al. (2012). An ATP-site on-off switch that restricts phosphatase accessibility of akt. Sci Signal 5: ra37.
163. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, et al. (2005). Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15: 761-764.
164. Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, et al. (2013). Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 20: 146-159.
165. Liu Y, Gray NS, (2006). Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2: 358-364.
166. Logue JS, Morrison DK, (2012). Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev 26: 641-650.
167. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. (2004). Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
168. London CA, (2013). Kinase dysfunction and kinase inhibitors. Vet Dermatol 24: 181-187, e139-140.
169. Lopez-Garcia LA, Schulze JO, Frohner W, Zhang H, Suss E, Weber N, et al. (2011). Allosteric regulation of protein kinase PKCζ by the N-terminal C1 domain and small compounds to the PIF-pocket. Chem Biol 18: 1463-1473.
170. Lowinger TB, Riedl B, Dumas J, Smith RA, (2002). Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 8: 2269-2278.
171. Luo J, Solimini NL, Elledge SJ, (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
172. Ma H, Deacon S, Horiuchi K, (2008). The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 3: 607-621.
173. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. (2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101: 2368-2373.
174. Malumbres M, Barbacid M, (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
175. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S, (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
176. Martiny-Baron G, Fabbro D, (2007). Classical PKC isoforms in cancer. Pharmacol Res 55: 477-486.
177. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. (2010). Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120: 1774-1785.
178. McDermott J, Jimeno A, (2014). Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Drugs Today (Barc) 50: 291-300.
179. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, et al. (2003). A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 48: 2652-2659.
180. Medina T, Amaria MN, Jimeno A, (2013). Dabrafenib in the treatment of advanced melanoma. Drugs Today (Barc) 49: 377-385.
181. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, et al. (2006). An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A 103: 3153-3158.
182. Mendoza MC, Er EE, Blenis J, (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328.
183. Minkovsky N, Berezov A, (2008). BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 9: 1336-1346.
184. Moebitz H, Fabbro D, (2012). Conformational bias: a key concept for protein kinase inhibition. Eur Pharm Rev 17: 41-51.
185. Morphy R, Rankovic Z, (2007). Fragments, network biology and designing multiple ligands. Drug Discov Today 12: 156-160.
186. Motzer RJ, Hoosen S, Bello CL, Christensen JG, (2006). Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 15: 553-561.
187. Muller S, Knapp S, (2010). Targeting kinases for the treatment of inflammatory diseases. Expert Opin Drug Discov 5: 867-881.
188. Murray PJ, (2007). The JAK-STAT signaling pathway: input and output integration. J Immunol 178: 2623-2629.
189. Nelson V, Ziehr J, Agulnik M, Johnson M, (2013). Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 6: 135-143.
190. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. (2013). The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 98: 1510-1516.
191. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, et al. (2013). Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 12: 589-597.
192. Nolen B, Taylor S, Ghosh G, (2004). Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15: 661-675.
193. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192-1197.
194. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. (2009). AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412.
195. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, et al. (2009). Inhibitor hijacking of Akt activation. Nat Chem Biol 5: 484-493.
196. O'Reilly T, McSheehy PM, (2010). Biomarker development for the clinical activity of the mTOr inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3: 65-79.
197. Over B, Wetzel S, Grutter C, Nakai Y, Renner S, Rauh D, et al. (2013). Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem 5: 21-28.
198. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, et al. (2007). Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2: 58-61.
199. Pao W, Hutchinson KE, (2012). Chipping away at the lung cancer genome. Nat Med 18: 349-351.
200. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
201. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al. (2002). Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9: 268-272.
202. Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu M, Weissig H, et al. (2007). Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46: 350-358.
203. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, et al. (2011). In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 18: 699-710.
204. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
205. Pender C, Goldfine ID, Manchem VP, Evans JL, Spevak WR, Shi S, et al. (2002). Regulation of insulin receptor function by a small molecule insulin receptor activator. J Biol Chem 277: 43565-43571.
206. Perez-Soler R, (2004). The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10: 4238s-4240s.
207. Plenge RM, Scolnick EM, Altshuler D, (2013). Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12: 581-594.
208. Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH, (2013). ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 9: 307-312.
209. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
210. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390.
211. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
212. Quintas-Cardama A, Kantarjian H, Cortes J, (2007). Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6: 834-848.
213. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. (2004). Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958-3965.
214. Rajakulendran T, Sicheri F, (2010). Allosteric protein kinase regulation by pseudokinases: insights from STRAD. Sci Signal 3: pe8.
215. Rauch J, Volinsky N, Romano D, Kolch W, (2011). The secret life of kinases: functions beyond catalysis. Cell Commun Signal 9: 23.
216. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. (2014). Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15: 143-155.
217. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370: 2071-2082.
218. Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, et al. (2013). Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53: 491-504.
219. Robak T, Robak E, (2012). Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 21: 921-947.
220. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. (2005). Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491-500.
221. Rodon J, Dienstmann R, Serra V, Tabernero J, (2013). Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10: 143-153.
222. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. (2011). mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1: 248-259.
223. Rommel C, (2010). Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases. Curr Top Microbiol Immunol 346: 279-299.
224. Rommel C, Camps M, Ji H, (2007). PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7: 191-201.
225. Rubin BP, Duensing A, (2006). Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 86: 981-986.
226. Sadowsky JD, Burlingame MA, Wolan DW, McClendon CL, Jacobson MP, Wells JA, (2011). Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc Natl Acad Sci U S A 108: 6056-6061.
227. Salama AK, Kim KB, (2013). Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother 14: 619-627.
228. Salt IP, Palmer TM, (2012). Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs 21: 1155-1167.
229. Sanchez-Martin M, Pandiella A, (2012). Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. Int J Cancer 131: 244-252.
230. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D, (2007). Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282: 32539-32548.
231. Sawyers C, (2004). Targeted cancer therapy. Nature 432: 294-297.
232. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28: 803-814.
233. Schmierer B, Hill CS, (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8: 970-982.
234. Scott JD, Pawson T, (2009). Cell signaling in space and time: where proteins come together and when they're apart. Science 326: 1220-1224.
235. Sellers WR, (2011). A blueprint for advancing genetics-based cancer therapy. Cell 147: 26-31.
236. Serra V, Scaltriti M, Prudkin L, Eichhorn PJA, Ibrahim YH, Chandarlapaty S, et al. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30: 2547-2557.
237. Shahda S, Saif MW, (2013). Regorafenib: from bench to bedside in colorectal cancer. Expert Rev Clin Pharmacol 6: 243-248.
238. Shaw AT, Yasothan U, Kirkpatrick P, (2011). Crizotinib. Nat Rev Drug Discov 10: 897-898.
239. She QB, Solit D, Basso A, Moasser MM, (2003). Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9: 4340-4346.
240. Shibuya M, Suzuki Y, (1993). Treatment of cerebral vasospasm by a protein kinase inhibitor AT 877. No to Shinkei 45: 819-824.
241. Shibuya M, Asano T, Sasaki Y, (2001). Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm. Acta Neurochir Suppl 77: 201-204.
242. Simmons DL, (2013). Targeting kinases: a new approach to treating inflammatory rheumatic diseases. Curr Opin Pharmacol 13: 426-434.
243. Singh J, Petter RC, Baillie TA, Whitty A, (2011). The resurgence of covalent drugs. Nat Rev Drug Discov 10: 307-317.
244. Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S, (2013). NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci U S A 110: E4437-E4445.
245. Sternberg C, (2009). A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). ASCO, Abstract No. 5021.
246. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C, (2014). The landscape of kinase fusions in cancer. Nat Commun 5: 4846.
247. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. (2003). Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46: 1116-1119.
248. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
249. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837.
250. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F, (1986). Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem Biophys Res Commun 135: 397-402.
251. Tao ZF, Wang L, Stewart KD, Chen Z, Gu W, Bui MH, et al. (2007). Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J Med Chem 50: 1514-1527.
252. Taylor SS, Kornev AP, (2011). Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36: 65-77.
253. Taylor SS, Kim C, Vigil D, Haste NM, Yang J, Wu J, et al. (2005). Dynamics of signaling by PKA. Biochim Biophys Acta 1754: 25-37.
254. Tecle H, Shao J, Li Y, Kothe M, Kazmirski S, Penzotti J, et al. (2009). Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK? Bioorg Med Chem Lett 19: 226-229.
255. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
256. Tomita N, Hayashi Y, Suzuki S, Oomori Y, Aramaki Y, Matsushita Y, et al. (2013). Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett 23: 1779-1785.
257. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. (2001). Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21: 499-512.
258. Trusolino L, Bertotti A, (2012). Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation. Cancer Discov 2: 876-880.
259. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105: 3041-3046.
260. Tummino PJ, Copeland RA, (2008). Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47: 5481-5492.
261. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. (2010). Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
262. Tzarum N, Komornik N, Ben Chetrit D, Engelberg D, Livnah O, (2013). DEF pocket in p38α facilitates substrate selectivity and mediates autophosphorylation. J Biol Chem 288: 19537-19547.
263. Ubersax JA, Ferrell JE Jr, (2007). Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 8: 530-541.
264. Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T, (2008). A peptoid 'antibody surrogate' that antagonizes VEGF receptor 2 activity. J Am Chem Soc 130: 5744-5752.
265. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4: 94-109.
266. Vanderpool D, Johnson TO, Ping C, Bergqvist S, Alton G, Phonephaly S, et al. (2009). Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 48: 9823-9830.
267. Vasquez EM, (2000). Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 57: 437-448, quiz 449-451.
268. Ventura JJ, Nebreda AR, (2006). Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 8: 153-160.
269. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H, (2004). Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 1697: 243-257.
270. Vieth M, Sutherland JJ, Robertson DH, Campbell RM, (2005). Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 10: 839-846.
271. Viola D, Cappagli V, Elisei R, (2013). Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol 9: 1083-1092.
272. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085-3096.
273. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr, (2005). Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 44: 7342-7372.
274. Wang X, Sun SY, (2009). Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 13: 1193-1203.
275. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F, (2007). Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 19: 55-60.
276. Weinstein IB, (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
277. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141.
278. West K, (2009). CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 10: 491-504.
279. Wiestner A, (2013). Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31: 128-130.
280. Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, et al. (2009). Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 387: 219-232.
281. Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, et al. (2007). Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg Med Chem 15: 3635-3648.
282. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim HD, et al. (2006). Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2: 54.
283. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
284. Workman P, Al-Lazikani B, (2013a). Drugging cancer genomes. Nat Rev Drug Discov 12: 889-890.
285. Workman P, Al-Lazikani B, Clarke PA, (2013b). Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol 13: 486-496.
286. Wright CJ, McCormack PL, (2013). Trametinib: first global approval. Drugs 73: 1245-1254.
287. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, et al. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16: 1722-1733.
288. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP, (2013). mTOR kinase structure, mechanism and regulation. Nature 497: 217-223.
289. Yang JC, (2013). A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncol 14: 564-565.
290. Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, et al. (2011). Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol 18: 177-186.
291. Yang X, Huang Y, Crowson M, Li J, Maitland ML, Lussier YA, (2010). Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J Biomed Inform 43: 376-384.
292. Yuan TL, Cantley LC, (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
293. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM, (2009). Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326: 1707-1711.
294. Zhang J, Yang PL, Gray NS, (2009). Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
295. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. (2010). Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506.
296. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. (2009). Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
297. Zhou W, Ercan D, Janne PA, Gray NS, (2011). Discovery of selective irreversible inhibitors for EGFR-T790M. ACS Med Chem Lett 21: 638-643.
298. Zuccotto F, Ardini E, Casale E, Angiolini M, (2010). Through the 'gatekeeper door': exploiting the active kinase conformation. J Med Chem 53: 2681-2694.